Research

#Covid-19 #Data #Drug delivery #Drug development #Drug discovery #Research

Interim data suggests drug may prevent cytokine storm

Clinical-stage drug development company Noxopharm has announced that in a cohort of 18 patients with moderately severe cases of Covid-19, interim data from its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with the worsening of the virus. “Until enough people are vaccinated to achieve… Read More

#News

#Clinical trial #Drug design #Drug development #Drug discovery #Research

Call to rethink “primitive” clinical trial approaches

Virtual clinical development specialist, Phesi, is calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analysed 330,000 clinical trials from the past 15 years and found the majority require substantial protocol amendments and… Read More

#News

#Biotherapeutics #Drug delivery #Drug development #Drug discovery #Research #Therapeutics

Making a difference in allergy and immune disorder treatments

Allergy Therapeutics is a pioneering immunology company, specialised in the research and development of allergy and immune disorder treatments that target the cause, rather than just manage the symptoms. Alan Bullimore, Head of Business Innovation spoke to Lu Rahman about the company’s work and the challenges and opportunities of this… Read More

#Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines #Research #Vaccines

Covid-19 vaccine responses to be studied in people with immune deficits

A study assessing how people with immune system deficiencies or dysregulations respond to Covid-19 vaccination has begun enrolling participants at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims… Read More

#News

Mosquito
#Clinical trial #Immunology / Virology & Vaccines #Malaria #Research #Vaccines

Malaria vaccine first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with The Lancet), they note that they are the first to… Read More

#News

#Cancer immunotherapy #Cancer research #Research

First large study of immunotherapy in black cancer patients

A new collaboration between Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute will help oncologists learn whether black and white cancer patients respond differently to immunotherapy treatment and seeks to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a two-year,… Read More

#Cancer Research #News

#Biotherapeutics #Cancer research #DNA #Genetics #Radiology #Research

Researchers identify new role for protein in treatment of cancer

In a study by Yale Cancer Centre, researchers report on the discovery of a new role for STimulator of INterferon Genes, or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumour DNA damage… Read More

#Cancer Research #News

#Cell and gene therapy #Genetics #Genetics / genomics #Research

Genetic variants that impact immune cell functioning identified

New research has found that certain genetic variants that cause modified protein binding in immune cells are also seen in those at high risk of some autoimmune diseases. Scientists from the Wellcome Sanger Institute, Josep Carreras Leukaemia Research Institute in Spain, and the MRC London Institute of Medical Sciences (LMS)… Read More

#News

#Drug development #Drug discovery #Research

New protein degradation centre to lead drug discovery revolution

A new translational research centre aims to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) will contain the latest facilities to allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has attracted billions of pounds of investment… Read More

#News

#Cancer research #Drug delivery #Drug development #Drug discovery #Research

Karen Vousden wins first Women in Cancer Research award

Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement… Read More

#Cancer Research #News

#Clinical trial #Depression #Drug development #Drug discovery #Research

Magic mushroom compound performs as well as leading antidepressant

In a small study carried out by researchers at the Centre for Psychedelic Research at Imperial College London, it was found that psilocybin, the active compound in magic mushrooms, may be at least as effective as a leading antidepressant medication in a therapeutic setting. In a rigorous trial which assessed… Read More

#News

#Antibiotics #Biomedical research #Drug discovery #Research

ANTRUK launches research grants programme for antibiotic resistance

Antibiotic Research UK (ANTRUK), a charity tackling bacterial antibiotic resistance, has launched its 2021 Small Research Grants / Career Development Awards scheme. This is the charity’s largest grants programme to date. The charity will be awarding one grant of up to £50,000 and six grants of up to £25,000 each. Read More

#News

#Cancer #Cancer research #DNA #Research

Kancera’s blockers may pave the way for treatment for ovarian cancer

Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian… Read More

#Cancer Research #News

#Clinical trial #Covid-19 #Drug development #Immunology / Virology & Vaccines #Research #Vaccines

NIH begins study of allergic reactions to Covid-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of… Read More

#Covid-19 #News

#AI #AI / data analytics / healthtech / informatics #Drug discovery #Research

Charles River and Valence partner to provide AI-enabled drug design

Charles River Laboratories and Valence Discovery have teamed up to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimisation. Building on research done by Valence’s founding team at Mila, a deep learning research institute, the Valence platform enables the design of small… Read More

#News

#Cancer research #Drug development #Genetics / genomes #Laboratory data #Research

‘Patchwork’ tumours prevalent across multiple cancer types

Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours,… Read More

#Cancer Research #News